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Abstract Lipoprotein lipase (LPL) plays a role in lipid usage
in skeletal muscle by hydrolyzing plasma triglycerides into fatty
acids, which are further utilized for L-oxidation. Lipid usage is
stimulated during fasting, diabetes mellitus and exercise, con-
comitant with enhanced LPL expression in skeletal muscle.
Here we show that the forkhead type transcription factor
FKHR is strongly induced in skeletal muscle in fasting mice,
in mice with streptozotocin-induced diabetes and in mice after
treadmill running. Ectopic expression of FKHR enhanced LPL
gene expression in C2C12 muscle cells in culture. These results
implicate FKHR as an important modulator of lipid metabolism
in skeletal muscle.
) 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Lipoprotein lipase (LPL, EC 3.1.1.34) plays a rate-limiting
role in lipid usage by hydrolyzing plasma triglycerides into
fatty acids, which are further utilized for L-oxidation in skel-
etal muscle [1,2]. Lipid usage is stimulated during fasting,
diabetes mellitus and exercise, concomitant with enhanced
LPL expression in skeletal muscle [1,3^5]. LPL is also ex-
pressed in tissues such as adipose tissue and liver, and the
regulation of the LPL gene has been studied in adipose tissue
and liver. Namely, in adipose tissue, LPL is up-regulated by a
nuclear receptor PPARQ (peroxisome proliferator-activated re-
ceptor Q) [6]. In liver, LPL is up-regulated by both SREBP1c
and PPARK [6,7]. The regulation of LPL expression, during
fasting, diabetes and exercise, may be mediated by the actions
of PPARK or SREBP1c, as both are abundantly expressed in
the skeletal muscle [8,9]. However, the precise mechanism of
LPL gene regulation in skeletal muscle is unclear.
FKHR (FOXO1), AFX (FOXO4) and FKHRL1 (FOX-
O3a) are a subfamily of forkhead type transcription factors,
also called the FOXO family [10]. In addition, FKHR and
AFX have been reported to act as cofactors to various nuclear
receptors [11,12], as part of a complex containing CBP/p300
[13,14], which plays critical roles in nuclear receptor signal
including PPAR [15^17]. The FOXO family is expressed in
skeletal muscle [18]. Indeed, FKHR (forkhead homolog in
rhabdomyosarcoma) was originally cloned from a rhabdo-
myosarcoma because of its aberrant fusion with another tran-
scription factor, PAX3, resulting from a chromosomal trans-
location t(2; 13) [19]. The resulting fusion protein PAX3^
FKHR is thought to play a role in muscle cell transformation
and rhabdomyosarcoma [19], but the physiological role of
FOXO family proteins in skeletal muscle is unclear.
In this study, we examined the possible involvement of the
FOXO family in the regulation of LPL gene expression in
skeletal muscle. We found that FKHR is induced in skeletal
muscle in which LPL gene expression is increased. Moreover,
retroviral overexpression of FKHR in C2C12 muscle cells
enhanced LPL gene expression, and addition of PPARK acti-
vator enhanced it further. Thus, our data indicated that
FKHR activates LPL gene expression in concert with
PPARK.
2. Materials and methods
2.1. RNA analysis
Northern blot analysis was performed as described in [9]. The loads
of total RNA applied to each gel were shown by ethidium bromide
staining of ribosomal RNAs. The cDNA fragments for LPL, AFX,
FKHRL1, CD36/FAT (fatty acid transporter), GLUT4, SREBP1
were obtained by polymerase chain reaction from ¢rst strand cDNA
using mouse skeletal muscle total RNA and HeLa total RNA for
AFX. First strand cDNA was prepared using a T-primed ¢rst strand
kit (Amersham Pharmacia Biotech). The ampli¢ed products were sub-
cloned into pGEM-T Easy Vector (Promega), and con¢rmed by se-
quencing. The GenBank accession numbers of ampli¢ed cDNAs are:
LPL, J03302; AFX, X93996; FKHRL1, AF114259; CD36/FAT,
L23108; and GLUT4, AF374266. Human FKHR cDNA was ob-
tained by screening a skeletal muscle cDNA library, and con¢rmed
by sequencing. PPARK cDNA was obtained from Dr. K. Umesono.
2.2. Stable cell lines
Phoenix 293 cells [20] were cultured in 90 mm dishes and trans-
fected at 70% con£uence by Lipofect Amine Plus (Invitrogen) accord-
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ing to the manufacturer’s instructions, with 2 Wg of pLNCX-derived
expression plasmid (Clontech) containing cDNA of FKHR or vector
alone. Viral supernatants were harvested 48 h after transfection. The
supernatants were added to dishes (90 mm in diameter) of C2C12 cells
at 50% con£uence in Dulbecco’s modi¢ed Eagle’s medium (DMEM)
containing 10% fetal calf serum (FCS) and 5 Wg/ml polybrene in a
¢nal volume of 5 ml. C2C12 cells were purchased from American
Type Culture Collection. Cells were split 1:10 24 h after infection
and replated in DMEM containing 10% FCS and 1 mg/ml G418 to
eliminate uninfected cells. After the drug selection, virally infected
stable cell lines were cultured to con£uence in DMEM containing
10% FCS. Cells were refed every 2 days. At 1 week post-con£uence,
cells were incubated for 6 h with or without 10 WM Wy14643 (Cal-
biochem) and used for the preparation of RNA.
2.3. Animal studies
C57BL/6J mice were obtained from Tokyo Laboratory Animal Sci-
ence (Tokyo) at 7 weeks of age and allowed free access to laboratory
food (on a caloric basis, 11% fat, 60% carbohydrate and 29% protein).
The mice were maintained at a constant temperature of 22‡C with a
¢xed arti¢cial light cycle (12 h light and 12 h dark). For treadmill
running experiments, mice performed 10% uphill treadmill running
exercise at 15 m/min for 45 min periods eight times (totally 6 h),
with 5 min rest intervals. After running, mice were allowed free access
to the laboratory food. At 2 h and 16 h after the exercise bout, mice
were killed and skeletal muscle (quadriceps) was isolated for RNA
preparation. For streptozotocin (STZ)-induced diabetes mice experi-
ments, mice were intrapentoneally injected with STZ (Wako Chem-
ical, Japan) at a dose of 100 mg per kg body weight in ice-cold 0.5
mol/l citrate bu¡er (pH 4.5). Control mice received citrate bu¡er only.
10 days after injection, mice were killed. Blood was collected from
abdominal aorta and glucose was determined using a Tidex kit (San-
kyo).
2.4. Statistical analyses
Statistical comparisons were made using Student’s t-test. Statistical
signi¢cance is de¢ned as P6 0.05.
3. Results
3.1. FOXO family expression is enhanced in skeletal muscle of
fasting mice
To study the potential role of the FOXO family in the
regulation of LPL gene expression in skeletal muscle by nutri-
tional status, which a¡ects the LPL mRNA level, we exam-
ined mice subjected to fasting and refeeding (Fig. 1). Blood
glucose levels were decreased by fasting and recovered by
refeeding (control, 155S 8.9 mg/ml; fasting 24 h, 81S 2.2
mg/ml, P6 0.01; refed, 137S 5.9 mg/ml). As expected, 24 h
and 48 h fasting increased the expression of mRNA for LPL.
Expression of CD36/FAT, a fatty acid utilization protein
[21], was also up-regulated by fasting. Interestingly, fasting
induced a parallel seven- to eight-fold increase in FKHR
and FKHRL1 mRNAs. AFX mRNA expression was up-regu-
lated two-fold by fasting. PPARK expression was also up-
regulated three-fold. All of these inductions were reversed
by refeeding. Expression of glucose transporter 4 (GLUT4),
an insulin-dependent glucose transporter [22], was not sig-
ni¢cantly changed by fasting. Refeeding up-regulated the ex-
pression of GLUT4, which is considered to contribute to gly-
cogen synthesis [23]. SREBP1, a regulator of lipogenesis genes
[24], was decreased by fasting and increased by refeeding.
Expression of FOXO family members was not to be corre-
lated with the expression of GLUT4 and SREBP1c. Ethidium
bromide staining of 28S RNA was shown (Fig. 1). The con-
tent of ribosomal RNA in total RNA was marginally de-
creased by fasting, which was consistent with previous study
[25].
3.2. Expression of FOXO family members is modulated in
skeletal muscle of mice with diabetes
Next, we examined the level of FKHR in skeletal muscle of
mice treated with STZ, which is the most commonly used
Fig. 1. FOXO family and LPL gene expressions are increased in the
skeletal muscle of fasted mice. Mice were divided into four experi-
mental groups. They were either allowed to feed ad libitum (con-
trol), or subjected to a 24 h fast or 48 h fast. Others were subjected
to a 48 h fast followed by 8 h of feeding (refed). A: Northern anal-
ysis was performed on total RNA (20 Wg per lane) isolated from
skeletal muscle (quadriceps). Each lane represents a sample from
an individual mouse. B: Relative densitometric levels of the auto-
radiogram are shown. Each value represents meanSS.E. (n=4).
***P6 0.001, **P6 0.01 and *P6 0.05 vs. control.
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experimental model of diabetes [26]. STZ-treated mice had
higher blood glucose levels (543S 20 mg/ml) than the controls
(181S 6.5 mg/ml, P6 0.001), indicating that STZ, used in
the experiment, worked well to disrupt insulin secretion. As
expected, LPL mRNA levels increased as shown in Fig. 2.
Expression of CD36/FAT was also signi¢cantly increased.
Moreover, FKHR mRNA levels were markedly elevated
in the skeletal muscle of these mice. AFX and FKHRL1
levels were also elevated. PPARK level was marginally in-
creased.
3.3. Expression of FOXO family members in skeletal muscle of
mice after exercise
Mice after a single bout of 6 h running (15 m/min, 10%
uphill), showed a three- to ¢ve-fold increase of FKHRL1 and
FKHR mRNAs in skeletal muscle 2 h after running. At 16 h
after exercise, the FKHRL1 and FKHR mRNAs had re-
turned to sedentary levels (Fig. 3). LPL expression was also
increased in skeletal muscle 2 h after running, and then re-
turned 16 h after exercise.
3.4. Expression of FKHR in C2C12 myocytes promotes
LPL gene expression
We determined the causal relationship between FKHR ex-
pression and other genes, which increased in parallel in skel-
etal muscle, by ectopically overexpressing FKHR in the
C2C12 myocyte cell line. We overexpressed FKHR, as
FKHR was most up-regulated in fasting, diabetes and exer-
cise, among the FOXO family. C2C12 cells were infected with
recombinant particles encoding FKHR or vector alone.
Northern blot analysis was performed to con¢rm the expres-
sion of the transduced FKHR gene (Fig. 4). Expression of
FKHR led to a marked increase in LPL mRNA compared
to the level in cells infected with the vector alone. Thus, LPL
appears to be a target of FKHR in skeletal muscle. In con-
trast to LPL, overexpression of FKHR had only a marginal
in£uence on CD36/FAT levels in C2C12 cells (Fig. 4). Then,
we incubated FKHR-C2C12 cells with Wy14643, a synthetic
PPARK activator, and measured the expression level of LPL.
The basal and Wy14643-induced expression levels of LPL
were markedly elevated in the cells overexpressing FKHR
(Fig. 4). CD36/FAT expression was also increased by
Wy14643, which is consistent with a previous ¢nding that
CD36/FAT expression is enhanced by PPAR [27^29]. The
Wy14643-induced expression was also marginally increased
in FKHR-overexpressing cells (Fig. 4).
4. Discussion
In this study, we showed that the expression of FOXO
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Fig. 2. FOXO family and LPL gene expressions are increased in the
skeletal muscle of insulin-de¢cient mice. Northern analysis was per-
formed on the total RNA (20 Wg per lane) isolated from skeletal
muscle of the STZ-diabetic mice. Mice of 9 weeks of age received
an intrapentoneal injection with sodium citrate solution (control) or
STZ (100 mg per kg body weight). After 10 days, the animals were
killed. A typical autoradiogram and its relative levels are shown.
Each lane represents a sample from an individual mouse. Each val-
ue represents meanSS.E. of four mice. **P6 0.01 and *P6 0.05
vs. control.
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Fig. 3. FOXO family and LPL gene expressions are increased in the skeletal muscle of exercised mice. Mice of 9 weeks of age were either kept
sedentary (control) or exercised by a 6 h treadmill run in a day. At 2 h and 16 h after the exercise bout, mice were killed and skeletal muscle
was isolated for RNA preparation. Schematic experimental design is shown in the ¢gure. A typical autoradiogram and its relative levels are
shown. Each lane represents a sample from an individual mouse. Each value represents meanSS.E. of six mice. ***P6 0.001, **P6 0.01 and
*P6 0.05 vs. control.
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family members, including that of FKHR, concomitant with
LPL expression is induced in skeletal muscle of fasting mice
and mice with STZ-treated diabetes, and after exercise. Ec-
topic expression of FKHR in C2C12 muscle cells induced
LPL gene expression, in combination with the physiological
data described above, indicating that LPL is a target of
FKHR in skeletal muscle.
A genetic study of Caenorhabditis elegans showed that a
forkhead transcription factor DAF16 functions as a suppres-
sor of insulin receptor signaling [30]. The FOXO family is
considered the mammalian counterpart of DAF16 [31].
Thus, the FOXO family is suggested to act, in mammals, as
a downstream player in insulin signaling. In liver, FKHR is
reported to activate the gene expression of glucose-6-phospha-
tase (G6Pase), a key gluconeogenesis enzyme [32,33]. Both
G6Pase and FKHR mRNAs are induced by glucocorticoid
[33], whose blood level is high in fasting, diabetes and after
exercise [1], and both mRNAs are suppressed by insulin [33].
FKHR may activate gluconeogenesis by increasing G6Pase
expression in the liver, and activate fatty acid usage in skeletal
muscle by increasing LPL expression and play roles in total
glucose metabolism in the human body.
What signal stimulates expression of FOXO family mem-
bers in fasting, diabetes and exercise in skeletal muscle? As
described above, glucocorticoid is a good candidate. On the
other hand, conditions like glucose starvation and exercise
have been described to increase AMP-activated protein kinase
(AMPK) activity [34]. AMPK is a serine/threonine kinase,
widely expressed in skeletal muscle, and whose activity re£ects
the energy status (AMP:ATP ratio) of a cell [34]. We also
speculate that AMPK may be involved in the up-regulation
of FOXO family in the skeletal muscle. In contrast to our
speculation, Barthel et al. reported that treatment of hepatic
cells with 5-aminoimidazole-4-carboxamide riboside (AI-
CAR), an activator of AMPK, repressed G6Pase expression
and led to disappearance of FKHR protein [35]. Possible in-
volvement of AMPK in the regulation of FOXO family in the
skeletal muscle should be studied in the near future.
FKHR can act as a cofactor protein of nuclear hormone
receptors [11,12] as part of a nuclear receptor cofactor com-
plex that includes CBP/p300 [13,14]. We observed that FKHR
could physically interact with the N-terminal (aa 1^721) and
C-terminal (1824^2441), but not other regions of CBP [15] by
a GST-pull-down assay (data not shown). LPL gene promoter
contains a PPAR-responsive element and some glucocorticoid
receptor-responsive elements [6,36]. Ectopic expression of
FKHR in C2C12 cells enhanced LPL gene expression, and
addition of Wy14643 enhanced it further (Fig. 4). These
data suggest that FKHR can activate LPL gene expression
in concert with PPARK. The detailed molecular mechanism,
including possible functional interaction between FKHR and
these nuclear receptors on LPL gene expression, should be
clari¢ed in the future.
Transgenic mice speci¢cally overexpressing LPL in skeletal
muscle have been reported. High levels of muscle LPL caused
insulin resistance in their skeletal muscle [37,38]. Insulin resis-
tance in skeletal muscle is considered to be involved in the
pathogenesis of diabetes [37]. In STZ-treated diabetic mice,
FKHR expression was induced in skeletal muscle coupled
with enhanced LPL expression (Fig. 2). Thus, it is conceivable
that enhanced expression of FKHR in skeletal muscle may be
involved in the pathogenesis of diabetes. Further study on the
molecular mechanism of FKHR action in skeletal muscle is
also important from a clinical viewpoint.
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